Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Roivant Sciences (ROIV) Long-Term Investments (2021 - 2025)

Roivant Sciences' Long-Term Investments history spans 5 years, with the latest figure at $433.9 million for Q4 2025.

  • For Q4 2025, Long-Term Investments rose 166.19% year-over-year to $433.9 million; the TTM value through Dec 2025 reached $433.9 million, up 166.19%, while the annual FY2025 figure was $302.9 million, 105.35% up from the prior year.
  • Long-Term Investments reached $433.9 million in Q4 2025 per ROIV's latest filing, up from $412.3 million in the prior quarter.
  • In the past five years, Long-Term Investments ranged from a high of $433.9 million in Q4 2025 to a low of $100.6 million in Q2 2021.
  • Average Long-Term Investments over 5 years is $209.5 million, with a median of $178.6 million recorded in 2023.
  • Peak YoY movement for Long-Term Investments: decreased 28.33% in 2024, then skyrocketed 166.19% in 2025.
  • A 5-year view of Long-Term Investments shows it stood at $215.7 million in 2021, then fell by 20.02% to $172.5 million in 2022, then dropped by 21.2% to $135.9 million in 2023, then increased by 19.92% to $163.0 million in 2024, then surged by 166.19% to $433.9 million in 2025.
  • Per Business Quant, the three most recent readings for ROIV's Long-Term Investments are $433.9 million (Q4 2025), $412.3 million (Q3 2025), and $283.8 million (Q2 2025).